At ASH 2019 it was reported that in relapsed AML cases the median number of coexistent mutations was three and that the most common mutations coexistent with IDH2 included NPM1 (7%), RUNX1 (6%), and FLT3 (5%) [23]. Here, FLT3 is linked to acute myeloid leukemia.